Table 4.
Variable | Genotypic frequencies | |||
---|---|---|---|---|
GG (N=103) | GC+CC (N=39) | OR (95% CI) | p value | |
Clinical Stage | ||||
Stage I/II | 68 (66.0%) | 20 (51.3%) | 1.00 | p=0.106 |
Stage III/IV | 35 (34.0%) | 19 (48.7%) | 1.846 (0.873-3.902) | |
Tumor size | ||||
≦ T2 | 70 (68.0%) | 20 (51.3%) | 1.00 | p=0.066 |
> T2 | 33 (32.0%) | 19 (48.7%) | 2.015 (0.950-4.275) | |
Lymph node metastasis | ||||
No | 99 (96.1%) | 37 (94.9%) | 1.00 | p=0.742 |
Yes | 4 (3.9%) | 2 (5.1%) | 1.338 (0.235-7.614) | |
Distant metastasis | ||||
No | 96 (93.2%) | 35 (89.7%) | 1.00 | p=0.491 |
Yes | 7 (6.8%) | 4 (10.3%) | 1.567 (0.432-5.682) | |
Vascular invasion | ||||
No | 89 (86.4%) | 27 (69.2%) | 1.00 | p=0.018* |
Yes | 14 (13.6%) | 12 (30.8%) | 2.825 (1.168-6.833) | |
Child-Pugh grade | ||||
A | 81 (78.6%) | 25 (64.1%) | 1.00 | p=0.075 |
B or C | 22 (21.4%) | 14 (35.9%) | 2.062 (0.921-4.618) | |
Anti-HCV | ||||
Negative | 88 (85.4%) | 33 (84.6%) | 1.00 | p=0.902 |
Positive | 15 (14.6%) | 6 (15.4%) | 1.067 (0.382-2.981) | |
Liver cirrhosis | ||||
Negative | 14 (13.6%) | 9 (23.1%) | 1.00 | p=0.171 |
Positive | 89 (86.4%) | 30 (76.9%) | 0.524 (0.206-1.334) |
The ORs with analyzed by their 95% CIs were estimated by logistic regression models.
> T2: multiple tumor more than 5 cm or tumor involving a major branch of the portal or hepatic vein(s)
* p value < 0.05 as statistically significant.